Pathology practice Medlab Clinical
(ASX:MDC) has announced it has received a licence from the Victorian government which allows the company to sell and supply cannabis.
The licence enables the company’s NabaBis and NanaBidal products to be sold in other states as well as Victoria.
The company’s Australian manufactured NabaBis cannabis-based medicine, which is currently in production, is expected to be available in late February 2018, sold under the TGA’s Special Access Scheme.
Medlab CEO Sean Hall said the continued support from the medical community, various states and the Federal Government for cannabis-based medicine is pleasing.
He said the company is seeking to make its medicines distinctive to give medical practitioners, the government and industry stakeholders such as the Australian Medical Association (AMA) confidence in prescribing its products.
Shares in Medlab Clinical
(ASX:MDC) are trading 24.69 per cent higher at $1.01.
